These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3132631)

  • 1. Desferrioxamine improves anaemia in haemodialysis patients without aluminum or iron overload.
    Cuvelier R; Deceuninck P
    Nephrol Dial Transplant; 1988; 3(1):104. PubMed ID: 3132631
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of desferrioxamine on anaemia of haemodialysis patients.
    Felipe C; Rivera M; Orofino L; Matesanz R; Ortuño J
    Nephrol Dial Transplant; 1988; 3(1):105-106. PubMed ID: 3132633
    [No Abstract]   [Full Text] [Related]  

  • 3. Desferrioxamine does not improve aluminium-unrelated anaemia of haemodialysis.
    Basile C; Scatizzi A
    Nephrol Dial Transplant; 1988; 3(3):355. PubMed ID: 3140114
    [No Abstract]   [Full Text] [Related]  

  • 4. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
    von Bonsdorff M; Sipilä R; Pitkänen E
    Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desferrioxamine, anaemia, and haemodialysis.
    Lancet; 1988 Jun; 1(8599):1405-6. PubMed ID: 2898087
    [No Abstract]   [Full Text] [Related]  

  • 6. Desferrioxamine versus erythropoietin for treatment of dialysis anaemia.
    Padovese P; Gallieni M; Galmozzi C; Brancaccio D
    Lancet; 1990 Jun; 335(8703):1465. PubMed ID: 1972238
    [No Abstract]   [Full Text] [Related]  

  • 7. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis.
    Seifert A; von Herrath D; Schaefer K
    Q J Med; 1987 Dec; 65(248):1015-24. PubMed ID: 3455553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
    Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
    Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Indications for desferrioxamine in patients with chronic renal insufficiency treated by dialysis].
    Simon P
    Nephrologie; 1986; 7(5):177-80. PubMed ID: 3822038
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy.
    Milne FJ; Sharf B; Bell P; Meyers AM
    Clin Nephrol; 1983 Oct; 20(4):202-7. PubMed ID: 6641027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microcytic anemia in dialysis patients.
    Grossman SD; Smith LE
    Am J Kidney Dis; 1988 Apr; 11(4):362. PubMed ID: 3354574
    [No Abstract]   [Full Text] [Related]  

  • 12. Desferrioxamine treatment for aluminium and iron overload in uraemic patients by haemodialysis or haemofiltration.
    Baldamus CA; Schmidt H; Scheuermann EH; Werner E; Kaltwasser JP; Schoeppe W
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():382-6. PubMed ID: 3991527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypercalcaemic osteomalacia and encephalopathy due to aluminium intoxication in haemodialysis patients. Clinical aspects and treatment with desferrioxamine.
    Mudde AH; Roodvoets AP; Van Groningen K
    Neth J Med; 1985; 28(1):6-11. PubMed ID: 3974771
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
    Ciancioni C; Poignet JL; Mauras Y; Panthier G; Delons S; Allain P; Man NK
    Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925
    [No Abstract]   [Full Text] [Related]  

  • 15. Improvement of anemia with deferoxamine in hemodialysis patients with aluminum-induced bone disease.
    Tielemans C; Collart F; Wens R; Smeyers-Verbeeke J; van Hooff I; Dratwa M; Verbeelen D
    Clin Nephrol; 1985 Nov; 24(5):237-41. PubMed ID: 4075595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of desferrioxamine in the treatment of dialysis encephalopathy.
    Ackrill P; Ralston AJ; Day JP
    Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985
    [No Abstract]   [Full Text] [Related]  

  • 17. Aluminum and iron overload in chronic dialysis.
    Ackrill P; Day JP; Ahmed R
    Kidney Int Suppl; 1988 Mar; 24():S163-7. PubMed ID: 3283407
    [No Abstract]   [Full Text] [Related]  

  • 18. Improvement in the erythropoiesis of chronic haemodialysis patients with desferrioxamine.
    de la Serna FJ; Praga M; Gilsanz F; Rodicio JL; Ruilope LM; Alcazar JM
    Lancet; 1988 May; 1(8593):1009-11. PubMed ID: 2896866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients.
    Chan D; Irish A; Dogra G
    Nephrology (Carlton); 2005 Aug; 10(4):336-40. PubMed ID: 16109077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
    Stojimirović B; Grujić-Adanja G
    Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.